Home » ATHENAGEN ADVANCES ATG002 TO CLINICAL TRIALS
ATHENAGEN ADVANCES ATG002 TO CLINICAL TRIALS
Athenagen has completed preparation for a Phase I/II clinical trial of its pro-angiogenesis topical wound healing agent ATG002.
Earlier this year the company filed an investigational new drug application with FDA for ATG002, a topical nicotinic acetylcholine (nACh) receptor agonist, to study the drug in patients with diabetic foot ulcers. The Phase I/II safety and proof-of-concept study will be conducted at leading wound care clinical sites in the U.S.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May